Digestive Diseases and Sciences

, Volume 51, Issue 4, pp 779–787 | Cite as

Effects of Cyclooxygenase-2 Inhibition on Serum and Tumor Gastrins and Expression of Apoptosis-Related Proteins in Colorectal Cancer

  • Peter C. Konturek
  • Kazimierz Rembiasz
  • Grzegorz Burnat
  • Stanisław J. Konturek
  • Marcin Tusinela
  • Władysław Bielanski
  • Jens Rehfeld
  • Danuta Karcz
  • Eckhart Hahn
Gastrointestinal Oncology


The objective of the present study was to determine the influence of cyclooxygenase-2 (COX-2) inhibition by Celecoxib (CLX) in humans with distal colorectal adenocarcinoma (CRC) on serum and tumor levels of progastrin and gastrin and serum levels of proinflammatory cytokines (IL-8, TNF-α). In addition, the effects of this CLX treatment on tumor and adjacent mucosa expression of gastrin, its receptors (CCK2), and COX-1 and COX-2, as well as protein expression of the active form of nuclear factor κ B (NFκ B) and the apoptotic-related proteins Bcl-2 and survivin, have been examined. Ten distal CRC patients were examined twice, once before and then after 14-day treatment with CLX (200 mg bid). Large biopsy samples were taken from the tumor and intact mucosa 10 cm above the tumor. For comparison, 20 age- and sex-matched healthy controls were enrolled and treated with CLX as CRC patients. Serum levels of IL-8 and TNF-α were measured by enzyme-linked immunosorbent assay, and serum levels of amidated gastrins and progastrin, by specific radioimmunoassay. The gene or protein expressions of progastrin, gastrin, CCK2, COX-1, COX-2, Bcl-2, and survivin as well as NFκ B were determined by RT-PCR or Western blot in biopsy samples of tumor and intact mucosa of CRC patients. Serum IL-8 and TNF-α values were severalfold higher in CRC patients than in controls. The increase in serum proinflammatory cytokines was accompanied by increased expression of the active form of NFκ B. Serum progastrin levels were also found to be significantly higher in CRC than in controls. Treatment of CRC with CLX resulted in a significant decrease in serum levels of progastrin and this was accompanied by an increment in tumor expression of COX-2 with a concomitant reduction in gastrin, Bcl-2, survivin, and NFκ B expression. We conclude that (1) distal CRC patients show significantly higher serum progastrin levels than matched healthy controls, confirming that this hormone may be implicated in rectal carcinogenesis; (2) CRC patients exhibit significantly higher serum levels of IL-8 and TNF-α than healthy controls, probably reflecting more widespread inflammatory reaction in the colonic mucosa in CRC; (3) gastrin, COX-2, Bcl-2, survivin, and NFκ B were overexpressed in CRC tumor compared to intact mucosa, but treatment with CLX significantly reduced serum levels of progastrin and IL-8 and TNF-α, which could mediate the up-regulation of COX-2 in CRC; and (4) CLX also enhanced expression of COX-2, while inhibiting the expression of gastrin, Bcl-2, survivin, and NFκ B, suggesting that COX-2 inhibition might be useful in chemoprevention against CRC, possibly due to suppression of the antiapoptotic proteins and reduction in progastrin-induced and NFκ B-promoted tumor growth.

Key Words

progastrin gastrin BCl-2 survivin COX-1 COX-2 colorectal cancer 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics 1998. CA Cancer J Clin 48:6–29, 1998PubMedGoogle Scholar
  2. 2.
    Jemal AT, Murray A, Samuels A, Ghafoor E, Ward, Rhun MJ: Cancer statistics. 2003 CA Cancer J Clin 53(1):5–26, 2003PubMedGoogle Scholar
  3. 3.
    Giovannucci E, Wilett WC: Dietary factors and risk of colon cancer. Ann Med 26:443–447, 1994PubMedGoogle Scholar
  4. 4.
    O’Brien MJ: The National Polyp Study: Patient and polyp characteristics associated with high grade dysplasia in colorectal adenomas. Gastroenterology 98:371–375, 1990PubMedGoogle Scholar
  5. 5.
    Eberhart CE, Coffey RJ, Radhika A, Giardiello, Ferrenback, DuBois RN: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenimals and adenoracinomas. Gastroenterology 1007(4):1183–1188, 1994Google Scholar
  6. 6.
    Konturek PC, Bielanski W, Konturek SJ, Hartwich A, Pierzchalsi P, Gonciarz M, Marlicz K, Starzynska T, Zuchowicz M, Darasz Z, Goetze J, Rehfeld JF, Hahn EG: Progastrin and cyclooxygenase-2 in colorectal cancer. Dig Dis Sci 47:1984–1991, 2002CrossRefPubMedGoogle Scholar
  7. 7.
    Mueller-Decker K, Albert C, Lukanov T: Cellular localization of cyclooxygenase isoenzymes in Crohn’s disease and colorectal cancer. Int J Colorectal Dis 14:212–228, 1999Google Scholar
  8. 8.
    Dimberg J, Samuelsson A, Hugander A: Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut 45(5):730–732, 1999PubMedGoogle Scholar
  9. 9.
    Sinicrope FA, Gill S: Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev 23:63–75, 2004CrossRefPubMedGoogle Scholar
  10. 10.
    Thun MJ, Namboodiri MM, Heath CW Jr: Aspirin use and reduced risk of fata colon cancer. N Engl J Med 325(23):1593–1596, 1991PubMedGoogle Scholar
  11. 11.
    Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Wilent WC: Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 121(4):241–246, 1994PubMedGoogle Scholar
  12. 12.
    Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Wilett WC, Speizer FE: Aspirin and the risk of colorectal cancer in women N Engl J Med 333(10):609–614, 1995CrossRefPubMedGoogle Scholar
  13. 13.
    Fenwick SW, Toogood GJ, Lodge JP, Hull MA: The effect of selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal liver metastases. Gastroenterology 125:716–729, 2003CrossRefPubMedGoogle Scholar
  14. 14.
    Rahme E, Barkun AN, Toubouti Y, Bardou M: The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasis occurrence and recurrence. Gastroenterology 125:404–412, 2003CrossRefPubMedGoogle Scholar
  15. 15.
    Peek RM Jr: Prevention of colorectal cancer through use of COX-2 selective inhibitor. Cancer Chemother Pharmacol 54 (Suppl 1):50–56, 2004Google Scholar
  16. 16.
    Johnson LR: Regulation of gastrointestinal mucosal growth. Physiol Rev 68:456–502, 1988PubMedGoogle Scholar
  17. 17.
    Sobhani I, Lehy T, Laurent-Puig P: Chronic endogenous hypergastrinemia in humans: evidence for a mitogenic effect on the colonic mucosa. Gastroenterology 105:22–30, 1993PubMedGoogle Scholar
  18. 18.
    Tukhar AS, Fremin O, Watson SA: The role of gastrin in colorectal carcinogenesis. Surgeon 2:251–257, 2004Google Scholar
  19. 19.
    Colucci R, Blandizzi C, Tanini M, Vassalle C, Breschi MC, Tacca MD: Gastrin promotes human colon cancer cell growth via CCK-2 receptor-mediated cyclooxygenase induction prostaglandin E(2) production. Br J Pharmacol 144:338–348, 2005CrossRefPubMedGoogle Scholar
  20. 20.
    Yao M, Song DH, Rana B, Wolfe MM: COX-2 selective inhibition reverses the trophic properties of gastrin in colorectal cancer. Br J Cancer 87:574–579, 2002CrossRefPubMedGoogle Scholar
  21. 21.
    Elder DJ, Halton DE, Hague A, Paraskeva C: Induction of apoptosis cell death in human colorectal carcinoma cell lines by cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res3(10):1679–1683, 1997PubMedGoogle Scholar
  22. 22.
    Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, Beauchamp RD, DuBois RN: Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 99(9):2254–2259, 1997PubMedGoogle Scholar
  23. 23.
    Shiff SJ, Qiao L, Tsai LL: Rigas B: Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 96:491–503, 1995PubMedGoogle Scholar
  24. 24.
    Piazza GA, Rahn AL, Krutzsch M, Sperl G, Paranka NS, Gross PH, Brendel K, Burt RW, Alberts DS, Pamukscu R: Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 55(4):3110–3116, 1995PubMedGoogle Scholar
  25. 25.
    Sinicrope FA, Gill S: Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev 23:63–75, 2004CrossRefPubMedGoogle Scholar
  26. 26.
    Yamamoto T, Yinn MJ, Lin KM, Gaynor RB: Sulindac inhibits activation of the NF-kappa B pathway. J Biol Chem 274:27307–27314, 1999PubMedGoogle Scholar
  27. 27.
    Lehman JM, Lemhard JM, Oliver BB, Ringlod GM, Kliewer SA: Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272:3406–3410, 1997CrossRefGoogle Scholar
  28. 28.
    He TC, Chan TA, Vogelstein B, Kinzler KW: PPRdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99:335–345, 1999CrossRefPubMedGoogle Scholar
  29. 29.
    Goel A, Dong KC, Ricciardiello L, Gasche C, Boland CR: A novel mechanism for aspirin—mediated growth inhibition of human colon cancer cells. Clin Cancer Res 9:383–390, 2003PubMedGoogle Scholar
  30. 30.
    Hartwich A, Konturek SJ, Pierzchalski P, Zuchowicz M, Labza H, Konturek PC, Karczewska E, Bielanski W, Marlicz K, Starzynska T, Lawniczak M, Hahn EG: Helicobacter pylori infection, gastrin, cyclooxygenase-2, and apoptosis in colorectal cancer. Int J Colorectal Dis 16:202–210, 2001CrossRefPubMedGoogle Scholar
  31. 31.
    Bielański W, Konturek SJ: New approach to 13C urea breath test: capsule-based modification with low-dose 13C—urea breath test in the diagnostic of Helicobacter pylori infection. J Physiol Pharmacol 47:545–553, 1996PubMedGoogle Scholar
  32. 32.
    Breuer-Katschinki B, Nemes K, Marr A, Rump B, Leiendecker B, Breuer N, Goebell H: Helicobacter pylori and the risk of colonic adenomas. Colorectal adenoma study group. Digestion 60:210–215, 1999Google Scholar
  33. 33.
    Gerlag DM, Ransone L, Tak PP, Han Z, Palanki M, Barbosa MS, Boyle D, Manning AM, Firestein GS: The effect of a T cell-specific NF-kappa B inhibitor in vitro cytokine production and collagen-induced arthritis J Immunol 165:1652–1658, 2000PubMedGoogle Scholar
  34. 34.
    Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 87:159–170, 1996CrossRefPubMedGoogle Scholar
  35. 35.
    Siddheshwar RK, Gray JG, Kelly SB: Plasma levels of progastrin but not amidated gastrin and glycine extended gastrin are elevated in patients with colorectal carcinoma. Gut 48:47–52, 2001CrossRefPubMedGoogle Scholar
  36. 36.
    Ciccotosto GD, McLeish A, Hardy KJ, Shulkes A: Expression, processing, and secretion of gastrin in patients with colorectal carcinoma. Gastroenterology 109:1142–1153, 1995CrossRefPubMedGoogle Scholar
  37. 37.
    Baldwin GS, Zhang QZ: Measurement of gastrin and transforming growth factor or α messenger RNA levels in colonic carcinoma cell lines by quantitative polymerase chain reaction. Cancer Res 52:2261–2267, 1992PubMedGoogle Scholar
  38. 38.
    Finley GG, Koski RA, Melhem MF, Pipas JM, Meisler AL: Expression of gastrin gene in the normal human colon and colorectal adenocarcinoma. Cancer Res 53:2919–2926, 1993PubMedGoogle Scholar
  39. 39.
    Smith AM, Watson SA: Review article: gastrin and colorectal cancer. Aliment Pharmacol Ther 14:1233–1247, 2000CrossRefGoogle Scholar
  40. 40.
    Dockray G, Varro A, Dimaline R, Wang T: The gastrins. Their production and biological activities. u Rev Physiol 63:119–139, 2001Google Scholar
  41. 41.
    Goetze JP, Nielsen FC, Burcharth F, Rehfeld JF: Closing the gastrin loop in pancreatic cancer. Cancer 88:2487–2494, 2000CrossRefPubMedGoogle Scholar
  42. 42.
    Caplin M, Khan K, Savage K, Rode J, Varro A, Michaeli D, Grimes S, Brett B, Pounder R, Dhillon A: Expression and processing of gastrin in hepatocellular carcinoma, fibroamellar carcinoma and colangiocarcinoma. J Hepatol 30:519–526, 1999CrossRefPubMedGoogle Scholar
  43. 43.
    Singh P, Velasco M, Given R, Varro A, Wang TC: Progastrin expression predisposes mice to colon carcinomas and adenomas in response to chemical carcinogen. Gastroenterology 119:162–171, 2000CrossRefPubMedGoogle Scholar
  44. 44.
    Biagini P, Monges G, Vuaroqueaux V, Parriaux D, Cantaloube JF, De Micco P: The human gastrin/cholecystokinin receptors: type B and type C expression in colonic tumors and cell lines. Life Sci 61(10):1009–1018, 1997CrossRefPubMedGoogle Scholar
  45. 45.
    Alvy A, Shulkes A, Baldwin GS: Gastrins, cholecystokinins and gastrointestinal tumors. Biochim Biophys Acta 1701:1–10, 2004Google Scholar
  46. 46.
    Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, Tiano HF, Morham SC, Smithies O, Langenbach R: Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60:4705–4708, 2000PubMedGoogle Scholar
  47. 47.
    Watson SA, Gilliam AD: G17DT–-a new weapon in the therapeutic armoury of gastrointestinal malignancy. Expert Opin Ther 1(2):309–317, 2001Google Scholar
  48. 48.
    Smith A, Justin T, Watson SA, Michaeli D, Broome P, Maxwell-Armstrong C: Clinical outcome of advanced colorectal cancer patients treated with anti-gastrin immunogen, gastrimmune. Br J Surg 85:1556, 1998Google Scholar
  49. 49.
    Ponelle T, Chapusot C, Martin L, Bouvier AM, Plenchette S, Faivre J, Solary E, Piard F: Cellular localization of survivin: impact on the prognosis in colorectal cancer. Cancer Res Clin Oncol (in press), 2005Google Scholar
  50. 50.
    Chen WC, Liu Q, Fu JX, Kang SY: Expression of survivin and its significance in colorectal cancer. World J Gastroenterol 10:2886–2889, 2004PubMedGoogle Scholar
  51. 51.
    Wu JT, Kral JG: The NF-kB/IkB signaling system: a molecular target in breast cancer therapy. J Surg Res123:158–169, 2005CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2006

Authors and Affiliations

  • Peter C. Konturek
    • 1
    • 5
  • Kazimierz Rembiasz
    • 2
  • Grzegorz Burnat
    • 1
  • Stanisław J. Konturek
    • 3
  • Marcin Tusinela
    • 2
  • Władysław Bielanski
    • 3
  • Jens Rehfeld
    • 4
  • Danuta Karcz
    • 2
  • Eckhart Hahn
    • 1
  1. 1.Department of MedicineUniversity Erlangen-NurembergErlangenGermany
  2. 2.Department of SurgeryJagiellonian University Medical CollegeCracowPoland
  3. 3.Department of PhysiologyJagiellonian University Medical CollegeCracowPoland
  4. 4.Department of Clinical Biochemistry, RigshospitaletUniversity of CopenhagenCopenhagenDenmark
  5. 5.First Department of MedicineUniversity Erlangen-NürnbergErlangenGermany

Personalised recommendations